Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

A Feasible and Acceptable Multicultural Psychosocial Intervention Targeting Symptom Management in the Context of Advanced Breast Cancer.

Teo I, Vilardaga JP, Tan YP, Winger J, Cheung YB, Yang GM, Finkelstein EA, Shelby RA, Kamal AH, Kimmick G, Somers TJ.

Psychooncology. 2019 Nov 8. doi: 10.1002/pon.5275. [Epub ahead of print]

PMID:
31703146
2.

PTH/PTHrP Receptor Signaling, Allostery, and Structures.

Sutkeviciute I, Clark LJ, White AD, Gardella TJ, Vilardaga JP.

Trends Endocrinol Metab. 2019 Nov;30(11):860-874. doi: 10.1016/j.tem.2019.07.011. Review.

PMID:
31699241
3.

Use of Backbone Modification To Enlarge the Spatiotemporal Diversity of Parathyroid Hormone Receptor-1 Signaling via Biased Agonism.

Liu S, Jean-Alphonse FG, White AD, Wootten D, Sexton PM, Gardella TJ, Vilardaga JP, Gellman SH.

J Am Chem Soc. 2019 Sep 18;141(37):14486-14490. doi: 10.1021/jacs.9b04179. Epub 2019 Sep 9.

PMID:
31496241
4.

Structure and dynamics of the active human parathyroid hormone receptor-1.

Zhao LH, Ma S, Sutkeviciute I, Shen DD, Zhou XE, de Waal PW, Li CY, Kang Y, Clark LJ, Jean-Alphonse FG, White AD, Yang D, Dai A, Cai X, Chen J, Li C, Jiang Y, Watanabe T, Gardella TJ, Melcher K, Wang MW, Vilardaga JP, Xu HE, Zhang Y.

Science. 2019 Apr 12;364(6436):148-153. doi: 10.1126/science.aav7942.

PMID:
30975883
5.

Ca2+ allostery in PTH-receptor signaling.

White AD, Fang F, Jean-Alphonse FG, Clark LJ, An HJ, Liu H, Zhao Y, Reynolds SL, Lee S, Xiao K, Sutkeviciute I, Vilardaga JP.

Proc Natl Acad Sci U S A. 2019 Feb 19;116(8):3294-3299. doi: 10.1073/pnas.1814670116. Epub 2019 Feb 4.

6.

Luminescence-activated nucleotide cyclase regulates spatial and temporal cAMP synthesis.

Naim N, White AD, Reece JM, Wankhede M, Zhang X, Vilardaga JP, Altschuler DL.

J Biol Chem. 2019 Jan 25;294(4):1095-1103. doi: 10.1074/jbc.AC118.004905. Epub 2018 Dec 17.

PMID:
30559293
7.

Reply to Ahluwalia et al.: Contributions of melatonin receptors are tissue-dependent.

Suofu Y, Carlisle DL, Vilardaga JP, Friedlander RM.

Proc Natl Acad Sci U S A. 2018 Feb 27;115(9):E1944. doi: 10.1073/pnas.1800449115. Epub 2018 Feb 9. No abstract available.

8.

Opioid therapy and persistent pain: can cognitive behavioral therapy help?

Van Denburg AN, Vilardaga JP, Shelby RA, Keefe FJ.

Pain. 2018 Mar;159(3):411-415. doi: 10.1097/j.pain.0000000000001091. Review. No abstract available.

PMID:
29084050
9.

Cdc42 activation couples fluid shear stress to apical endocytosis in proximal tubule cells.

Bhattacharyya S, Jean-Alphonse FG, Raghavan V, McGarvey JC, Rbaibi Y, Vilardaga JP, Carattino MD, Weisz OA.

Physiol Rep. 2017 Oct;5(19). pii: e13460. doi: 10.14814/phy2.13460. Epub 2017 Oct 16.

10.

Dual role of mitochondria in producing melatonin and driving GPCR signaling to block cytochrome c release.

Suofu Y, Li W, Jean-Alphonse FG, Jia J, Khattar NK, Li J, Baranov SV, Leronni D, Mihalik AC, He Y, Cecon E, Wehbi VL, Kim J, Heath BE, Baranova OV, Wang X, Gable MJ, Kretz ES, Di Benedetto G, Lezon TR, Ferrando LM, Larkin TM, Sullivan M, Yablonska S, Wang J, Minnigh MB, Guillaumet G, Suzenet F, Richardson RM, Poloyac SM, Stolz DB, Jockers R, Witt-Enderby PA, Carlisle DL, Vilardaga JP, Friedlander RM.

Proc Natl Acad Sci U S A. 2017 Sep 19;114(38):E7997-E8006. doi: 10.1073/pnas.1705768114. Epub 2017 Sep 5.

11.

Design and validation of the first cell-impermeant melatonin receptor agonist.

Gbahou F, Cecon E, Viault G, Gerbier R, Jean-Alphonse F, Karamitri A, Guillaumet G, Delagrange P, Friedlander RM, Vilardaga JP, Suzenet F, Jockers R.

Br J Pharmacol. 2017 Jul;174(14):2409-2421. doi: 10.1111/bph.13856. Epub 2017 Jun 11.

12.

β2-adrenergic receptor control of endosomal PTH receptor signaling via Gβγ.

Jean-Alphonse FG, Wehbi VL, Chen J, Noda M, Taboas JM, Xiao K, Vilardaga JP.

Nat Chem Biol. 2017 Mar;13(3):259-261. doi: 10.1038/nchembio.2267. Epub 2016 Dec 26.

13.

Transmission electron microscopy for the evaluation and optimization of crystal growth.

Stevenson HP, Lin G, Barnes CO, Sutkeviciute I, Krzysiak T, Weiss SC, Reynolds S, Wu Y, Nagarajan V, Makhov AM, Lawrence R, Lamm E, Clark L, Gardella TJ, Hogue BG, Ogata CM, Ahn J, Gronenborn AM, Conway JF, Vilardaga JP, Cohen AE, Calero G.

Acta Crystallogr D Struct Biol. 2016 May;72(Pt 5):603-15. doi: 10.1107/S2059798316001546. Epub 2016 Apr 26.

14.

Actin-Sorting Nexin 27 (SNX27)-Retromer Complex Mediates Rapid Parathyroid Hormone Receptor Recycling.

McGarvey JC, Xiao K, Bowman SL, Mamonova T, Zhang Q, Bisello A, Sneddon WB, Ardura JA, Jean-Alphonse F, Vilardaga JP, Puthenveedu MA, Friedman PA.

J Biol Chem. 2016 May 20;291(21):10986-1002. doi: 10.1074/jbc.M115.697045. Epub 2016 Mar 23.

15.

Studying the regulation of endosomal cAMP production in GPCR signaling.

Gidon A, Feinstein TN, Xiao K, Vilardaga JP.

Methods Cell Biol. 2016;132:109-26. doi: 10.1016/bs.mcb.2015.10.007. Epub 2015 Dec 24.

16.

Regulation of Ligand and Shear Stress-induced Insulin-like Growth Factor 1 (IGF1) Signaling by the Integrin Pathway.

Tahimic CG, Long RK, Kubota T, Sun MY, Elalieh H, Fong C, Menendez AT, Wang Y, Vilardaga JP, Bikle DD.

J Biol Chem. 2016 Apr 8;291(15):8140-9. doi: 10.1074/jbc.M115.693598. Epub 2016 Feb 10.

17.

The Polycystin-1, Lipoxygenase, and α-Toxin Domain Regulates Polycystin-1 Trafficking.

Xu Y, Streets AJ, Hounslow AM, Tran U, Jean-Alphonse F, Needham AJ, Vilardaga JP, Wessely O, Williamson MP, Ong AC.

J Am Soc Nephrol. 2016 Apr;27(4):1159-73. doi: 10.1681/ASN.2014111074. Epub 2015 Aug 26.

18.

PTH receptor-1 signalling-mechanistic insights and therapeutic prospects.

Cheloha RW, Gellman SH, Vilardaga JP, Gardella TJ.

Nat Rev Endocrinol. 2015 Dec;11(12):712-24. doi: 10.1038/nrendo.2015.139. Epub 2015 Aug 25. Review.

19.
20.

Endosomal generation of cAMP in GPCR signaling.

Vilardaga JP, Jean-Alphonse FG, Gardella TJ.

Nat Chem Biol. 2014 Sep;10(9):700-6. doi: 10.1038/nchembio.1611. Review.

21.

Uncovering caffeine's adenosine A2A receptor inverse agonism in experimental parkinsonism.

Fernández-Dueñas V, Gómez-Soler M, López-Cano M, Taura JJ, Ledent C, Watanabe M, Jacobson KA, Vilardaga JP, Ciruela F.

ACS Chem Biol. 2014 Nov 21;9(11):2496-501. doi: 10.1021/cb5005383. Epub 2014 Oct 2.

22.

Endosomal GPCR signaling turned off by negative feedback actions of PKA and v-ATPase.

Gidon A, Al-Bataineh MM, Jean-Alphonse FG, Stevenson HP, Watanabe T, Louet C, Khatri A, Calero G, Pastor-Soler NM, Gardella TJ, Vilardaga JP.

Nat Chem Biol. 2014 Sep;10(9):707-9. doi: 10.1038/nchembio.1589. Epub 2014 Jul 27.

23.

Randomized controlled trial of cognitive behavioral therapy and acceptance and commitment therapy for social phobia: outcomes and moderators.

Craske MG, Niles AN, Burklund LJ, Wolitzky-Taylor KB, Vilardaga JC, Arch JJ, Saxbe DE, Lieberman MD.

J Consult Clin Psychol. 2014 Dec;82(6):1034-48. doi: 10.1037/a0037212. Epub 2014 Jul 7.

24.

Ezrin-radixin-moesin-binding phosphoprotein 50 (EBP50) and nuclear factor-κB (NF-κB): a feed-forward loop for systemic and vascular inflammation.

Leslie KL, Song GJ, Barrick S, Wehbi VL, Vilardaga JP, Bauer PM, Bisello A.

J Biol Chem. 2013 Dec 20;288(51):36426-36. doi: 10.1074/jbc.M113.483339. Epub 2013 Nov 6.

25.

Noncanonical control of vasopressin receptor type 2 signaling by retromer and arrestin.

Feinstein TN, Yui N, Webber MJ, Wehbi VL, Stevenson HP, King JD Jr, Hallows KR, Brown D, Bouley R, Vilardaga JP.

J Biol Chem. 2013 Sep 27;288(39):27849-60. doi: 10.1074/jbc.M112.445098. Epub 2013 Aug 9.

26.

Improving therapist psychological flexibility while training acceptance and commitment therapy: a pilot study.

Luoma JB, Vilardaga JP.

Cogn Behav Ther. 2013;42(1):1-8. doi: 10.1080/16506073.2012.701662.

PMID:
23505991
27.

Kinetics and dynamics in the G protein-coupled receptor signaling cascade.

Vilardaga JP, Romero G, Feinstein TN, Wehbi VL.

Methods Enzymol. 2013;522:337-63. doi: 10.1016/B978-0-12-407865-9.00016-9.

PMID:
23374192
28.

Noncanonical GPCR signaling arising from a PTH receptor-arrestin-Gβγ complex.

Wehbi VL, Stevenson HP, Feinstein TN, Calero G, Romero G, Vilardaga JP.

Proc Natl Acad Sci U S A. 2013 Jan 22;110(4):1530-5. doi: 10.1073/pnas.1205756110. Epub 2013 Jan 7.

29.

Non-canonical signaling of the PTH receptor.

Vilardaga JP, Gardella TJ, Wehbi VL, Feinstein TN.

Trends Pharmacol Sci. 2012 Aug;33(8):423-31. doi: 10.1016/j.tips.2012.05.004. Epub 2012 Jun 16. Review.

30.

Anabolic action of parathyroid hormone regulated by the β2-adrenergic receptor.

Hanyu R, Wehbi VL, Hayata T, Moriya S, Feinstein TN, Ezura Y, Nagao M, Saita Y, Hemmi H, Notomi T, Nakamoto T, Schipani E, Takeda S, Kaneko K, Kurosawa H, Karsenty G, Kronenberg HM, Vilardaga JP, Noda M.

Proc Natl Acad Sci U S A. 2012 May 8;109(19):7433-8. doi: 10.1073/pnas.1109036109. Epub 2012 Apr 25.

31.

Sympathetic control of bone mass regulated by osteopontin.

Nagao M, Feinstein TN, Ezura Y, Hayata T, Notomi T, Saita Y, Hanyu R, Hemmi H, Izu Y, Takeda S, Wang K, Rittling S, Nakamoto T, Kaneko K, Kurosawa H, Karsenty G, Denhardt DT, Vilardaga JP, Noda M.

Proc Natl Acad Sci U S A. 2011 Oct 25;108(43):17767-72. doi: 10.1073/pnas.1109402108. Epub 2011 Oct 11.

32.

Extra-long Gαs variant XLαs protein escapes activation-induced subcellular redistribution and is able to provide sustained signaling.

Liu Z, Turan S, Wehbi VL, Vilardaga JP, Bastepe M.

J Biol Chem. 2011 Nov 4;286(44):38558-69. doi: 10.1074/jbc.M111.240150. Epub 2011 Sep 2.

33.

Studying ligand efficacy at G protein-coupled receptors using FRET.

Vilardaga JP.

Methods Mol Biol. 2011;756:133-48. doi: 10.1007/978-1-61779-160-4_6.

34.

Dynamic Na+-H+ exchanger regulatory factor-1 association and dissociation regulate parathyroid hormone receptor trafficking at membrane microdomains.

Ardura JA, Wang B, Watkins SC, Vilardaga JP, Friedman PA.

J Biol Chem. 2011 Oct 7;286(40):35020-9. doi: 10.1074/jbc.M111.264978. Epub 2011 Aug 8.

35.

Visualizing microtubule-dependent vasopressin type 2 receptor trafficking using a new high-affinity fluorescent vasopressin ligand.

Chen S, Webber MJ, Vilardaga JP, Khatri A, Brown D, Ausiello DA, Lin HY, Bouley R.

Endocrinology. 2011 Oct;152(10):3893-904. doi: 10.1210/en.2011-1049. Epub 2011 Aug 9.

36.

Recording kinetics of adrenergic receptor activation in live cells.

Vilardaga JP.

Curr Top Membr. 2011;67:101-11. doi: 10.1016/B978-0-12-384921-2.00005-7. Review. No abstract available.

37.

Retromer terminates the generation of cAMP by internalized PTH receptors.

Feinstein TN, Wehbi VL, Ardura JA, Wheeler DS, Ferrandon S, Gardella TJ, Vilardaga JP.

Nat Chem Biol. 2011 May;7(5):278-84. doi: 10.1038/nchembio.545. Epub 2011 Mar 27.

38.

G-protein-coupled receptor heteromer dynamics.

Vilardaga JP, Agnati LF, Fuxe K, Ciruela F.

J Cell Sci. 2010 Dec 15;123(Pt 24):4215-20. doi: 10.1242/jcs.063354.

39.

Theme and variations on kinetics of GPCR activation/deactivation.

Vilardaga JP.

J Recept Signal Transduct Res. 2010 Oct;30(5):304-12. doi: 10.3109/10799893.2010.509728. Review.

40.

Molecular basis of parathyroid hormone receptor signaling and trafficking: a family B GPCR paradigm.

Vilardaga JP, Romero G, Friedman PA, Gardella TJ.

Cell Mol Life Sci. 2011 Jan;68(1):1-13. doi: 10.1007/s00018-010-0465-9. Epub 2010 Aug 12. Review.

41.

Formation of a ternary complex among NHERF1, beta-arrestin, and parathyroid hormone receptor.

Klenk C, Vetter T, Zürn A, Vilardaga JP, Friedman PA, Wang B, Lohse MJ.

J Biol Chem. 2010 Sep 24;285(39):30355-62. doi: 10.1074/jbc.M110.114900. Epub 2010 Jul 23.

42.

Lighting up multiprotein complexes: lessons from GPCR oligomerization.

Ciruela F, Vilardaga JP, Fernández-Dueñas V.

Trends Biotechnol. 2010 Aug;28(8):407-15. doi: 10.1016/j.tibtech.2010.05.002. Epub 2010 Jun 9. Review.

43.

On the expanding terminology in the GPCR field: the meaning of receptor mosaics and receptor heteromers.

Agnati LF, Guidolin D, Vilardaga JP, Ciruela F, Fuxe K.

J Recept Signal Transduct Res. 2010 Oct;30(5):287-303. doi: 10.3109/10799891003786226. Review.

44.

Sustained cyclic AMP production by parathyroid hormone receptor endocytosis.

Ferrandon S, Feinstein TN, Castro M, Wang B, Bouley R, Potts JT, Gardella TJ, Vilardaga JP.

Nat Chem Biol. 2009 Oct;5(10):734-42. doi: 10.1038/nchembio.206. Epub 2009 Aug 23.

45.

Cell migration is regulated by platelet-derived growth factor receptor endocytosis.

Kawada K, Upadhyay G, Ferandon S, Janarthanan S, Hall M, Vilardaga JP, Yajnik V.

Mol Cell Biol. 2009 Aug;29(16):4508-18. doi: 10.1128/MCB.00015-09. Epub 2009 Jun 15.

46.

Evidence for distinct antagonist-revealed functional states of 5-hydroxytryptamine(2A) receptor homodimers.

Brea J, Castro M, Giraldo J, López-Giménez JF, Padín JF, Quintián F, Cadavid MI, Vilaró MT, Mengod G, Berg KA, Clarke WP, Vilardaga JP, Milligan G, Loza MI.

Mol Pharmacol. 2009 Jun;75(6):1380-91. doi: 10.1124/mol.108.054395. Epub 2009 Mar 11.

PMID:
19279328
47.

GPCR and G proteins: drug efficacy and activation in live cells.

Vilardaga JP, Bünemann M, Feinstein TN, Lambert N, Nikolaev VO, Engelhardt S, Lohse MJ, Hoffmann C.

Mol Endocrinol. 2009 May;23(5):590-9. doi: 10.1210/me.2008-0204. Epub 2009 Feb 5. Review.

48.

Fluorescence resonance energy transfer analysis of alpha 2a-adrenergic receptor activation reveals distinct agonist-specific conformational changes.

Zürn A, Zabel U, Vilardaga JP, Schindelin H, Lohse MJ, Hoffmann C.

Mol Pharmacol. 2009 Mar;75(3):534-41. doi: 10.1124/mol.108.052399. Epub 2008 Dec 23.

PMID:
19106230
49.

Prolonged signaling at the parathyroid hormone receptor by peptide ligands targeted to a specific receptor conformation.

Okazaki M, Ferrandon S, Vilardaga JP, Bouxsein ML, Potts JT Jr, Gardella TJ.

Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16525-30. doi: 10.1073/pnas.0808750105. Epub 2008 Oct 22.

50.

Effects of the renal medullary pH and ionic environment on vasopressin binding and signaling.

Zalyapin EA, Bouley R, Hasler U, Vilardaga JP, Lin HY, Brown D, Ausiello DA.

Kidney Int. 2008 Dec;74(12):1557-67. doi: 10.1038/ki.2008.412. Epub 2008 Aug 27.

Supplemental Content

Loading ...
Support Center